Sanofi studies show benefits of new type 2 diabetes therapy

Sanofi has announced new clinical trial data showing the benefits of a promising combination therapy for type 2 diabetes.

Results from the pivotal phase III LixiLan-O and LixiLan-L clinical trials highlighted the safety and efficacy of the company's investigational titratable fixed-ratio combination of basal insulin glargine and the GLP-1 receptor agonist lixisenatide in adults with type 2 diabetes.

Both studies met their primary endpoints, demonstrating statistically superior reductions in average blood glucose over the previous three months versus comparators, while the safety profile of the treatment was also shown to be positive.

Results from these studies have been submitted to regulators in the US and Europe, with rulings expected in the next few months.

Dr Jorge Insuasty, senior vice-president and global head of development at Sanofi, said: "These studies reflect Sanofi's commitment to innovative approaches in developing medicines intended to help patients meet their needs throughout their diabetes journey."

The company presented the findings of these two studies at the recent American Diabetes Association Scientific Sessions, which were held in New Orleans earlier this week.